id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-030578-8c77d59p	Combs, Joshua C.	SARS CoV-2: a review of current treatment regimens	2020-08-11		.txt	text/plain	625	31	31	While supportive treatment remains the standard of care, additional therapeutic regimens including antivirals, monoclonal antibodies, antibiotics, anti-inflammatories, immunoenhancers, vitamins, systemic steroids, inhalants, anticoagulants, and convalescent plasma are showing promise. While supportive treatment remains the standard of care, additional therapeutic regimens are showing promise. Categorically, current treatment options can be broken into the following: antiviral, monoclonal antibody, antibiotic, anti-inflammatory, immunoenhancer, vitamin, systemic steroid, inhalant, anticoagulant, and convalescent plasma [2, 3] . Monoclonal antibodies such as Tocilizumab, Sarilumab, and Bevacizumab have shown promise in reduction of disease severity by limiting interleukin-6 production, thereby lessening the cytokine storm and associated acute respiratory distress syndrome seen in severe COVID-19 cases [3] . Systemic steroids and inhalant treatments such as nitric oxide are not recommended for individual treatment of COVID-19 but may be effective as supportive therapy in those with severe viral-associated acute respiratory distress syndrome [2] .	./cache/cord-030578-8c77d59p.txt	./txt/cord-030578-8c77d59p.txt